Search

everythinglearnresearchcommunity

for

Search:↓

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Ozenoxacin reduces sebum production, helping manage acne.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Imuvert can prevent some chemotherapy-induced hair loss.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

Bortezomib chemotherapy can cause temporary skin rashes.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Entospletinib effectively prevents eye and skin GVHD in mice.

Inhibiting ornithine decarboxylase may help prevent certain skin cancers.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.